 Biogen Inc. BIIB, -0.15 and partner Eisai Co. Ltd ESALY, 1.13 4523, -2.11 said Friday an advisory committee to the European Medicines Agency has adopted a negative opinion on its Alzheimers treatment aducanumab, known as aduhelm in the U.S. The company was seeking an authorization for the treatment in patients in the early stages of the disease known as mild cognitive impairment. This decision is aligned to the negative trend vote of the committee in November 2021. 